Stockreport

Motif Bio REVIVE-1 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Clinical Infectious Diseases

MOTIF BIO PLC ADRS  (MTFB) 
US:NASDAQ Investor Relations: ir.motifbio.com
PDF Iclaprim met the primary endpointIclaprim was well tolerated in the study Additional data from the previously announced topline results are included in the publication  [Read more]